Eye Allergy Therapeutics Market Report 2025

The eye allergy therapeutics market size has grown strongly in recent years. It will grow from $3.04 billion in 2024 to $3.23 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. Several factors contributed to growth during the historic period, including the increasing prevalence of allergic conjunctivitis, greater awareness of eye allergies, higher levels of urban pollution, improved availability of advanced treatments, and enhancements in healthcare infrastructure.

The eye allergy therapeutics market size is expected to see strong growth in the next few years. It will grow to $4.1 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. Growth in the forecast period is expected to be driven by the expanding elderly population, greater adoption of biologic treatments, increased funding for ophthalmic research, heightened awareness of eye allergy symptoms, and progress in drug delivery technologies. Key trends during this time will include developments in personalized medicine, innovations in sustained-release drug formulations, the integration of digital diagnostic tools, advances in biologic therapies, and new non-invasive treatment approaches.

The increasing prevalence of eye allergies is expected to drive the growth of the eye allergy therapeutics market in the coming years. Eye allergies occur when the immune system reacts to allergens, causing inflammation and irritation in the eyes. The rise in eye allergy cases is largely attributed to worsening environmental pollution, which increases exposure to airborne allergens and triggers more allergic responses. Eye allergy therapeutics help manage these allergies by reducing inflammation, relieving itching and redness, and preventing allergic reactions to offer effective symptom relief. For example, in May 2025, the National Library of Medicine, a US-based biomedical resource, reported that ocular allergy (OA) affected 49.3% (n=207) of cases studied, with seasonal allergic conjunctivitis (SAC) making up 90.3%, primarily among 14-year-olds (23.4%) and females (58.8%). Hence, the growing incidence of eye allergies is fueling the expansion of the eye allergy therapeutics market.

Key players in the eye allergy therapeutics market are focusing on innovative products, including itch relief treatments, to provide quicker symptom relief, improve patient comfort, and increase accessibility through over-the-counter options. Eye allergy itch relief therapeutics specifically target itching caused by allergic eye reactions. For instance, in August 2024, Glenmark Pharmaceuticals Limited, an India-based company, introduced Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC), designed for twice-daily use. This formulation delivers fast and lasting relief from symptoms of allergic conjunctivitis such as itching, redness, and watery eyes. The OTC availability caters to the rising demand for self-care products and broadens consumer access within the eye care market.

In July 2023, Harrow Inc., a US-based ophthalmic pharmaceutical provider, acquired the Canadian and US ophthalmic portfolio from Santen Pharmaceutical Co. Ltd. for an undisclosed amount. This acquisition expanded Harrow’s presence in North America and added established eye care brands to its portfolio. The move supports Harrow’s ambition to become a leading supplier of comprehensive ophthalmic solutions. Santen Pharmaceutical Co. Ltd. is a Japan-based manufacturer specializing in eye allergy therapeutics.

Major players in the eye allergy therapeutics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Alcon Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Limited, Hikma Pharmaceuticals plc, Santen Pharmaceutical Co. Ltd., Zydus Lifesciences Limited, Stallergenes Greer Ltd., HAL Allergy B.V., Ocular Therapeutix Inc., Tarsus Pharmaceuticals Inc., Nicox S.A.

North America was the largest region in the eye allergy therapeutics market in 2024. The regions covered in eye allergy therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the eye allergy therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The eye allergy therapeutics market consists of sales of artificial tears and lubricants, natural or herbal remedies, and non-steroidal anti-inflammatory drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The eye allergy therapeutics market research report is one of a series of new reports that provides eye allergy therapeutics market statistics, including the eye allergy therapeutics industry global market size, regional shares, competitors with the eye allergy therapeutics market share, detailed eye allergy therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the eye allergy therapeutics industry. This eye allergy therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Eye allergy therapeutics are treatments designed to alleviate symptoms caused by allergic reactions in the eyes, such as itching, redness, swelling, and tearing. These treatments work by addressing the allergic response and may involve the use of antihistamines, mast cell stabilizers, or corticosteroids.

The primary drug categories for eye allergy treatments include antihistamines, mast cell stabilizers, dual-action agents, corticosteroids, decongestants, immunotherapy, and others. Antihistamines function by blocking histamine receptors, helping to reduce itching, redness, and swelling linked to allergies. Common types of eye allergies include seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), and giant papillary conjunctivitis. These medications can be administered through various routes such as topical, oral, injectable, ocular, and systemic methods. Distribution occurs via hospital pharmacies, retail pharmacies, online pharmacies, among other channels. The main end users encompass hospitals, clinics, homecare providers, pharmacies, and research institutions.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.